Valeant’s Permax withdrawn
Executive Summary
Valeant Pharmaceuticals will voluntarily withdraw its Parkinson's disease therapy Permax (pergolide) due to the high rate of heart valve damage associated with the drug, FDA announces March 29. The agency requested the withdrawal due to results of two studies published in the January issue of the New England Journal of Medicine that showed a five-fold increase in the risk of valvulopathy. Generic versions of Permax, marketed by Par and Teva, will also be withdrawn...